Albireo Pharma (NASDAQ:ALBO) Lifted to Hold at BidaskClub

BidaskClub upgraded shares of Albireo Pharma (NASDAQ:ALBO) from a sell rating to a hold rating in a research report sent to investors on Thursday, BidAskClub reports.

ALBO has been the topic of a number of other reports. HC Wainwright reiterated a buy rating and issued a $60.00 target price on shares of Beyondspring in a report on Wednesday, July 10th. William Blair reiterated a buy rating on shares of Albireo Pharma in a report on Monday, July 15th. Wedbush set a $9.00 price objective on GameStop and gave the company a buy rating in a research note on Thursday, July 11th. Zacks Investment Research cut Hess Midstream Partners from a hold rating to a sell rating in a research note on Tuesday, May 14th. Finally, Cowen restated a market perform rating and set a $99.00 price objective (up from $97.00) on shares of United Continental in a research note on Wednesday, April 17th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of Buy and an average price target of $54.25.

Shares of ALBO opened at $28.22 on Thursday. Albireo Pharma has a 12-month low of $19.10 and a 12-month high of $38.69. The stock has a fifty day moving average price of $31.51.

Albireo Pharma (NASDAQ:ALBO) last issued its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.37) by ($0.02). Albireo Pharma had a negative return on equity of 47.03% and a negative net margin of 2,900.81%. The firm had revenue of $0.57 million during the quarter, compared to the consensus estimate of $1.20 million. On average, analysts predict that Albireo Pharma will post -5.99 earnings per share for the current year.

A number of large investors have recently modified their holdings of ALBO. Federated Investors Inc. PA increased its position in shares of Albireo Pharma by 22.8% during the 1st quarter. Federated Investors Inc. PA now owns 719,595 shares of the biopharmaceutical company’s stock valued at $23,178,000 after purchasing an additional 133,449 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Albireo Pharma by 40.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 116,223 shares of the biopharmaceutical company’s stock valued at $2,850,000 after purchasing an additional 33,390 shares during the last quarter. Marshall Wace North America L.P. purchased a new stake in shares of Albireo Pharma during the 1st quarter valued at $816,000. Chicago Capital LLC increased its position in shares of Albireo Pharma by 6.8% during the 2nd quarter. Chicago Capital LLC now owns 202,241 shares of the biopharmaceutical company’s stock valued at $6,520,000 after purchasing an additional 12,833 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Albireo Pharma by 11.3% during the 4th quarter. Geode Capital Management LLC now owns 97,434 shares of the biopharmaceutical company’s stock valued at $2,390,000 after purchasing an additional 9,922 shares during the last quarter. Institutional investors and hedge funds own 70.42% of the company’s stock.

About Albireo Pharma

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Further Reading: Quiet Period

Analyst Recommendations for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.